Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging The Visual Response Score and the Change in Total Lesion Glycolysis

Larson, Steven M.; Erdi, Yusuf E.; Akhurst, Timothy; Mazumdar, Madhu; Macapinlac, Homer A.; Finn, Ronald D.; Casilla, Cecille; Fazzari, Melissa; Srivastava, Neil C.; Yeung, Henry; Humm, John L.; Guillem, José G.; Downey, Robert J.; Karpeh, Martin S.; Cohen, Alfred E.; Ginsberg, Robert J.

doi:10.1016/s1095-0397(99)00016-3

Cited by 525 publications

(395 citation statements)

References 25 publications

Supporting

Mentioning

375

Contrasting

Unclassified

Order By: Relevance

“…On the contrary, the BOT group mainly consisted with mucinous tumor (n=5/7), and the average value of SUV max was 2.0. Mucinous adenocarcinomas account for less than 5 % of all epithelial ovarian cancers, whereas up to 80 % of mucinous tumors are benign or borderline tumors [20]. Thus, it could be useful to measure preoperatively SUV values in predicting histologic type of epithelial ovarian tumors, especially combining with anatomical imaging findings by CT or MR.…”

Section: Discussionmentioning

confidence: 99%

Differential Diagnosis of Borderline Ovarian Tumors from Stage I Malignant Ovarian Tumors using FDG PET/CT

Kim

Chung

et al. 2013

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose Borderline ovarian tumors (BOTs) are more common in young women of reproductive age, and exhibit a better prognosis than malignant ovarian tumors (MOTs). Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) were compared in their ability to differentiate BOTs from stage I MOTs. Methods Among 173 patients who had preoperative FDG PET/CT due to ovarian neoplasms between November 2006 and March 2009, there were 13 patients with BOTs or stage I MOTs. For differential diagnosis of the two tumors, cancer antigen-125 (CA-125) level, the longest diameter of tumors, metabolic indices including maximum standardized uptake value (SUV max ), and volumetric indices including metabolic tumor volume (MTV) were compared, respectively. Results The BOT group (n=7) was comprised of five mucinous and two serous tumors, and the MOT group (n=6) was comprised of three endometrioid, two clear cell and one mucinous tumors. Among the comparisons between two groups, SUV max of the BOT group was significantly lower than that of the MOT group (2.9±1.5 vs. 6.6±2.9, p=0. 0223); otherwise, no significant difference was found in age, CA-125, diameter, or MTV. By receiver-operating characteristic curve analysis, SUV max of 3.7 was the best cutoff value to differentiate BOTs from stage I MOTs, with a sensitivity of 83.3 % and specificity of 85.7, and the area under curve of 0.893 (p=0.0001, 95 % CI: 0.601∼0.993). Conclusions We demonstrated that SUV max could distinguish BOTs from stage I MOTs, with a high sensitivity and specificity. Metabolic indices determined by FDG PET/CT were more suitable than volumetric indices for differential diagnosis of the two tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

Differential Diagnosis of Borderline Ovarian Tumors from Stage I Malignant Ovarian Tumors using FDG PET/CT

Kim

Chung

et al. 2013

Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…It can be shown that the standardized uptake value (SUV max ) is proportional to the rate of glucose metabolism (7). Now that PET-FDG is being widely used in clinical oncology, it has become evident that the rate of glycolysis, as captured by the SUV max or related uptake measures, is an important predictor of the biological aggressiveness across multiple tumor types, including brain tumor (8), sarcoma (9), thyroid cancer (10), head and neck cancer (11), non-small cell lung cancer (12,13), malignant mesothelioma (14), prostate cancer (15), small cell lung cancer (16), esophageal carcinoma, pancreatic tumors (17,18), and non-Hodgkin's lymphoma (19).…”

mentioning

confidence: 99%

Positron Emission Tomography-Based Molecular Imaging in Human Cancer

Larson

2004

Clinical Cancer Research

View full text Add to dashboard Cite

“…SUV maximum (SUVmax), SUV mean, total lesion glycolysis (TLG; FDG-PET), total lesion proliferation (TLP; FLT-PET), and functional tumor volume (FTV) were calculated. TLG and TLP were defined as SUVmean multiplied by FTV as is considered standard [20].…”

Section: Pet Image Analysismentioning

confidence: 99%

Long-term Results of a Pilot Study Comparing FLT-PET and FDG-PET in the Evaluation of Response to Treatment in Advanced Head and Neck and Esophageal Malignancies

RS¹,

Vj²,

Rl³

et al. 2017

J Nucl Med Radiat Ther

View full text Add to dashboard Cite

Objective: We prospectively compared FDG-PET and FLT-PET in assessing patient responses to induction cetuximab and/or chemoradiotherapy (CRT) for advanced head and neck squamous cell carcinoma (HNSCC) and esophageal cancer (EC). Methods:Sixteen patients were enrolled, 9 with HNSCC and 7 with EC. FDG-PET and FLT-PET scans were performed at baseline and two weeks into chemoradiotherapy (CRT) for patients with EC. Patients with HNSCC received two weeks of induction chemotherapy along with post-induction PET scans prior to starting CRT in addition to the baseline and intra-chemoradiotherapy PET scans. Changes in SUVmax and total lesion glycolysis/ proliferation (TLG/TLP) were compared with baseline.Results: Median follow-up for living patients was 6.0 years. Median overall survival (OS) was 3.3 years and progression-free survival (PFS) was 2.5 years. Patients with HNSCC had higher baseline SUVmax, TLG and TLP than those with EC. Changes in SUVmax, TLG and TLP after induction chemotherapy or during CRT did not correlate with PFS or OS. Those with >40% decline in SUVmax on FDG-PET six weeks after completing CRT had better PFS (p<0.0001) and OS (p=0.0003) than those with less of a response. In addition, >70% decrease in posttreatment TLG correlated with better PFS (p=0.03) and OS (p=0.04). Conclusions:Functional imaging performed early during chemoradiotherapy for advanced HNSCC and EC is feasible. Changes on post-induction and intra-CRT FLT and FDG PET did not correlate with PFS or OS. However, better PFS and OS were seen in patients with >40% decline in SUVmax and >70% decrease in TLG on FDG-PET performed six weeks after completing CRT. Further research is needed to determine the prognostic impact of PET performed during chemotherapy and radiotherapy.

show abstract

Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging The Visual Response Score and the Change in Total Lesion Glycolysis

Cited by 525 publications

References 25 publications

Differential Diagnosis of Borderline Ovarian Tumors from Stage I Malignant Ovarian Tumors using FDG PET/CT

Differential Diagnosis of Borderline Ovarian Tumors from Stage I Malignant Ovarian Tumors using FDG PET/CT

Positron Emission Tomography-Based Molecular Imaging in Human Cancer

Long-term Results of a Pilot Study Comparing FLT-PET and FDG-PET in the Evaluation of Response to Treatment in Advanced Head and Neck and Esophageal Malignancies

Contact Info

Product

Resources

About